Sinae Bromhexine Hydrochloride fabrica, supplementum, Factory

Quiescere potes ex officina nostra emere Bromhexine Hydrochloride in Sinis. Pharmaceutical Run'an professionalis Sinarum Bromhexine Hydrochloride fabrica et supplementum, qualitas products alta praebere possumus. Grata res emendas ex officina nostra.

Hot Products

  • 122111-03-9

    122111-03-9

    Seres productum nomen: Gemcitabine HCl
    Sinensis alias: Gemcitabine Hydrochloride; Gemcitabine HCl API; Gemcitabine Hydrochloride API; 4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl] -1h-pyrimidin-2-one hydrochloride; Anti-tumor Gemcitabine
    Anglicus productum nomen: Gemcitabinum hydrochloridum
    CAS#122111-03-9
  • CAS 145108-58-3

    CAS 145108-58-3

    CAS 145108-58-3 medicamentum sedationi est, cerussa sponte solutum in aqua.
  • CAS NO. 608141-41-9

    CAS NO. 608141-41-9

    Seres operis nomen: Aprester
    Sinensis alias: (S) -2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl] -4-acetylaminoisoindoline-1,3 -diketone
    Anglicus operis nomen: Apremilast
    CAS NO. 608141-41-9
    Formulae hypotheticae: C22H24N2O7S
    Pondus hypotheticum: 460.5
  • CAS#122111-03-9

    CAS#122111-03-9

    Seres productum nomen: Gemcitabine HCl
    Sinensis alias: Gemcitabine Hydrochloride; Gemcitabine HCl API; Gemcitabine Hydrochloride API; 4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl] -1h-pyrimidin-2-one hydrochloride; Anti-tumor Gemcitabine
    Anglicus productum nomen: Gemcitabinum hydrochloridum
    CAS#122111-03-9
  • 62-23-7

    62-23-7

    Formulae hypotheticae: C7H5NO4
    Pondus hypotheticum: 167.12
    62-23-7 est pro biosynthesi aureothinae antibioticae et pro synthesi organica.
  • Dexmedetomidine Hydrochloridis API

    Dexmedetomidine Hydrochloridis API

    Dexmedetomidine hydrochloridis API sedationis medicamento est, pulveris albi qui in aqua libere solubilis est.

Mitte Inquisitionem

X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept